<DOC>
	<DOCNO>NCT02559973</DOCNO>
	<brief_summary>This single-center , randomize , open-label , single-dose , parallel-group study enroll randomize approximately 48 subject ( achieve 36 completers ) opioid use disorder ( OUD ) seek treatment OUD . The study include Residential ( Inpatient ) Non-Residential ( Outpatient ) Period .</brief_summary>
	<brief_title>Pharmacokinetics , Safety , Tolerability Depot Buprenorphine Three Different Molecular Weights Treatment-Seeking Subjects With Opioid Use Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Buprenorphine , Naloxone Drug Combination</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>Currently meet DSM5 criterion moderate severe opioid use disorder ( OUD ) Is seek treatment OUD Body mass index : ≥ 18.0 ≤ 35.0 kg/m^2 Females : Female individual childbearing potential ( defined woman surgically sterile postmenopausal least 1 year prior informed consent ) must negative serum pregnancy test prior enrollment must agree use medically acceptable mean contraception Screening least 6 month last dose Investigational Medicinal Product ( IMP ) . Males : Male individual female partner childbearing potential must agree use medically acceptable contraception signing informed consent form least 6 month last dose IMP . Male individual must also agree donate sperm study 6 month receive last dose IMP . Have normal electrocardiogram ( ECG ) ECG clinically significant finding opinion Investigator medically qualify subinvestigator Screening predose Day 1 . Agree take buprenorphinecontaining product , administer current study , throughout duration study . Willing adhere study procedure provide write informed consent prior start study procedure . Current diagnosis , OUD , require chronic opioid treatment . Pregnant lactating female . Have ECG demonstrate correct QT interval use Fridericia 's calculation ( QTcF ) &gt; 450 msec male QTcF &gt; 470 msec female upon admission residential facility prior administration RBP6000 . Currently meet criterion diagnosis moderate severe substance use disorder , DSM5 criterion , substance opioids , and/or tobacco . Had significant traumatic injury , major surgery , open biopsy within 4 week prior sign inform consent form . Used buprenorphinecontaining product within 14 day prior sign inform consent form . Have history suicidal ideation within 30 day prior sign inform consent form prior study drug administration Have history presence allergic adverse response ( include rash anaphylaxis ) buprenorphine , naloxone , methadone , ATRIGEL Delivery System . Individuals positive urine drug screen ( UDS ) prior admission residential facility barbiturate , benzodiazepine , buprenorphine , methadone .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Buprenorphine</keyword>
	<keyword>opioid use disorder</keyword>
</DOC>